In a nutshell The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers. Some background The main treatment for early...Read More
Ongoing treatment(s)-Chemotherapy Posts on Medivizor
Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.
In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...Read More
What is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?
In a nutshell This study aimed to investigate the outcomes for acute myeloid leukemia (AML) patients treated with venetoclax (Venclexta) and azacitidine (Vidaza) who achieved complete remission (CR) and minimal measurable residual disease (MRD) after treatment. This study concluded that patients who achieved both CR and minimal...Read More
Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.
In a nutshell This study evaluated the occurrence and clinical predictors of peripheral neuropathy (PN; nerve damage) in long-term survivors of breast cancer (BC). The data showed that PN is an important long-term consequence of taxane-based chemotherapy in survivors of BC. Some background BC is one of the most common forms of cancer in women....Read More
Evaluating eribulin versus other treatment options in women with advanced breast cancer.
In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...Read More
Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.
In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...Read More
Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia
In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL). This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...Read More
Evaluating the best timing of surgery after chemotherapy in patients with breast cancer
In a nutshell This study evaluated the impact of different times after chemotherapy until breast cancer surgery on complications after surgery and survival outcomes. The data showed the optimal time to surgery (TTS) was between 21 and 28 days after chemotherapy in these patients. Some background Breast cancer (BC) is one of...Read More
Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?
In a nutshell This study investigated if reducing therapy duration could reduce side effects in patients but still be effective in patients with stage II colorectal cancer (CRC). This study showed that in certain patients a 3-month treatment duration can be considered. Some background Patients with colorectal cancer (CRC) can be treated...Read More
Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?
In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...Read More
Can a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?
In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite. Some background...Read More
How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?
In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...Read More